Steatosis News and Research

RSS

Perceived stigmatization is common among patients with NAFLD, study finds

About seven out of ten patients (69%) who suffer from non-alcoholic fatty liver disease (NAFLD) perceive some stigmatization in their daily life, according to a study led by a team of the University of Barcelona, the Liver and Digestive Diseases Networking Biomedical Research Centre, the Hospital Clínic de Barcelona and the August Pi i Sunyer Biomedical Research Institute.

12 May 2022

Researchers uncover a new protective mechanism against non-alcoholic fatty liver disease

Non-alcoholic fatty liver disease (NAFLD), commonly known as fatty liver disease, is a prevalent disease frequently seen in obese people. Having high fat content in the liver is detrimental as it is strongly associated with severe health problems like diabetes, high blood pressure, and liver cancer.

20 Apr 2022

Researchers illuminate the link between autophagy and the body's metabolic response to fasting

The coming of spring harkens spring cleaning; a time to de-clutter your home and discard things that are no longer needed. In the body, a cellular process called autophagy occurs regularly to "de-clutter" our cells.

15 Mar 2022

Maternal metabolic syndrome can switch on imprinted gene associated with NAFLD in offspring

New research from North Carolina State University has found that an imprinted gene associated with development of non-alcoholic fatty liver disease (NAFLD) is switched on in mice who nurse from mothers with metabolic syndrome, even when those mice are not biologically related.

7 Feb 2022

Role of leptin in immune modulation and pathophysiology of COVID-19

A recent review paper in the journal Frontiers in Physiology discusses the role of leptins in infection with SARS-CoV-2 that triggered the ongoing COVID-19 pandemic.

13 Jan 2022

COVID-19 symptoms found to vary in different immune contexts

In a new study, researchers studied the kinetics of host response to SARS-CoV-2 infection in a Syrian hamster model, tracking disease pathology, viral loads, antibody responses, and inflammatory cytokine production in multiple organs.

11 Jan 2022

Sarcopenia and COVID-19

The present study attempts to investigate if sarcopenia, which is a condition where there is loss of skeletal muscle mass and function, may result in poor clinical outcomes in COVID-19 patients.

13 Dec 2021

Monitoring cellular metabolism for NAFLD/NASH liver disease research

In this interview, Jolanta Vidugiriene, a Senior Research Scientist at Promega Corporation, talks to News-Medical about tools for studying metabolism in NAFLD/NASH research.

From Promega Corporation 22 Nov 2021

Two new proteins identified as therapeutic targets for preventing NAFLD and associated liver cancer

An international study led by the Lipids&Liver research team at the UPV/EHU-University of the Basque Country, the results of which have recently been published in the prestigious journal Cancer Research, has demonstrated that inhibiting either of the proteins E2F1 or E2F2 in the liver protects against the development of obesity-driven nonalcoholic fatty liver disease and its progression to cancer.

29 Jul 2021

A new method for generating metabolic profiles of single cells

Scientists from the European Molecular Biology Laboratory and the German Cancer Research Center have presented a new method for generating metabolic profiles of individual cells.

6 Jul 2021

New study attempts to characterize long-COVID in all its complexity

In a new meta-study, a large subset of reports on post-viral complications in individuals following a SARS-CoV-2 infection have been organized and categorized, mapping 287 unique clinical findings related to long-COVID.

5 Jul 2021

Study finds nutritional benefits of Connecticut-grown sugar kelp

When most Americans think of seaweed, they probably conjure images of a slimy plant they encounter at the beach. But seaweed can be a nutritious food too.

24 Jun 2021

British Liver Trust calls for action to address rising obesity rates that fuel liver disease crisis

The British Liver Trust is calling for greater awareness of a silent yet serious form of fatty liver disease, non-alcohol related steatohepatitis (NASH), as one million adults were reported to have been admitted to hospital with obesity-related conditions in 2020.

14 Jun 2021

Melatonin prevents kidney damage caused by metabolic complications of obesity

Scientists from the University of Granada (UGR), the Hospital Universitario La Paz (Madrid), and the University of Texas (USA) have taken an important step in the fight against kidney damage and its progression towards kidney failure, which is closely related to diabesity (obesity and its type 2 diabetes) and its complications.

27 May 2021

Researchers reveal the positive effects of exercise on the liver

Non-alcoholic fatty liver disease (NAFLD) is the most common liver disorder worldwide, affecting as much as a quarter of humanity. It is characterized by fat accumulation in liver cells and may progress to inflammation, cirrhosis and liver failure.

12 Apr 2021

Researcher get federal grant to study how gut microbiota and inflammation promote metabolic syndrome

Dr. Andrew Gewirtz, a professor in the Institute for Biomedical Sciences at Georgia State University, has received a four-year federal grant just over $2 million to study how inflammation and altered gut microbiota, the microorganisms living in the intestine, influence the development of a group of diseases referred to as metabolic syndrome.

18 Mar 2021

Study describes a safe potential therapeutic tool for liver regeneration

A new study led by researchers at the Center for Regenerative Medicine at Boston University School of Medicine (BUSM) and Boston Medical Center (BMC) now describes a safe new potential therapeutic tool for the recovery of liver function in chronic and acute liver diseases.

27 Jan 2021

Even mild fatty liver disease associated with higher risk of all-cause mortality

Non-alcoholic fatty liver disease, NAFLD, affects nearly one in four adults in Europe and the U.S. Earlier research has demonstrated an increased risk of death in patients with NAFLD and advanced fibrosis or cirrhosis.

12 Oct 2020

Glucagon resistance: A new biological concept in the fight against diabetes

Researchers from the University of Copenhagen are introducing a new biological concept in the fight against diabetes: glucagon resistance.

17 Sep 2020

CN Bio partners with Imperial College London to uncover therapeutic targets for alcoholic hepatitis

CN Bio, a leading cell culture company, that has developed single and multi-organ microphysiological systems to improve the accuracy and efficiency of drug discovery, today announced a collaboration with Imperial College London, a world-class research university.

10 Sep 2020